Skip to main content
Glama

Take The Meeting

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. Changed3 schema fields changed
    • changedInput schema / properties / type / description
      Previous value: -"Entity type. v1 supports \"company\"."New value: +"Entity type: \"company\" or \"drug\"."
    • changedInput schema / properties / type / enum
      Previous value: -[
-  "company"
-]New value: +[
+  "company",
+  "drug"
+]
    • changedInput schema / properties / value / description
      Previous value: -"Ticker, CIK, or company name (e.g., \"AAPL\", \"0000320193\", \"Apple\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."
  3. Added

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

The annotations (readOnlyHint, openWorldHint, idempotentHint, destructiveHint=false) already establish a safe, read-only operation. The description adds substantial behavioral detail: graceful degradation when GLEIF/OpenFIGI are down, cascade through multiple endpoints, labeling of identifier sources, explicit `unresolved` field for failures, ambiguity handling via `figi_candidates`, and the ISIN-to-LEI mapping for non-US issuers. This goes far beyond the annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is long but every sentence adds value—examples, usage directive, supported types, behavioral caveats, and parameter nuance. It is front-loaded with the purpose and 'Use FIRST' guidance, then systematically covers company details and drug details. While it could be tightened, the structure is logical and the verbosity is justified given the tool's complexity.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a tool with two entity types, multiple data sources, ambiguity handling, and no output schema, the description covers the key contextual points: input formats, source fallback, unresolved identifier disclosure, and the exact matching behavior for bonds. It also explains the ISIN-to-LEI path, which is a non-obvious use case. Nothing an agent needs to call it correctly appears missing.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100% and both parameters have descriptions. The description enriches the 'value' parameter significantly with critical guidance: for bonds, pass the exact issuer name as printed, never the full noun phrase, because trailing security-class words match nothing. It also explains the accepted input formats for company (ticker, CIK, name) and drug (brand or generic). This is essential meaning not present in the schema.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description clearly states the tool resolves user-spoken names into canonical/official identifiers, listing specific examples ('ticker for…', 'CIK for…'), and explicitly differentiates it from siblings by saying 'Use FIRST whenever you have a name but need an ID'. It covers multiple entity types and explains its cross-source nature, making the purpose unambiguous and distinct.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description gives a strong directive: 'Use FIRST whenever you have a name but need an ID' and explains when it applies for company and drug resolution. It also clarifies that it replaces 2-3 manual lookups. However, it does not explicitly mention when NOT to use it or name alternative tools (e.g., if you already have an ID, use entity_profile) beyond implying it's the first stop. This is a minor gap, but the guidance is clear enough.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Take The Meeting toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.7/5.0
Disambiguation3/5

Most tools have distinct, well-documented roles, but the set includes two effectively identical routers (ask_pipeworx and ask_pipeworx_beta, with the latter explicitly matching the former right now) and a dense cluster of six Polymarket tools that an agent must read carefully to choose among. This is more than a minor overlap, though the detailed descriptions prevent it from being complete chaos.

Naming Consistency3/5

Everything is snake_case, which is a plus, but the patterns are inconsistent: some tools are verb_noun (resolve_entity, validate_claim, list_subscriptions), some are noun phrases (entity_profile, bet_research, recent_alerts), some use brand prefixes (ask_pipeworx*, polymarket_*, pipeworx_*), and take_the_meeting_evaluate is a sentence-like outlier. The prefixes do provide grouping, but the naming doesn't give a predictable action structure.

Tool Count2/5

32 top-level tools is above the 25+ threshold and will bloat an agent's tool-selection surface, especially because the server name 'Take The Meeting' suggests a narrow meeting tool while 31 of the tools are unrelated Pipeworx/data features. Even as a broad data-research server, several tools could be collapsed (the ask variants, the Polymarket family), so the count feels inflated.

Completeness2/5

For the purpose implied by the server name and the lone meeting tool, the surface is severely incomplete: there is no way to list or fetch meetings, access calendar/attendee context, or do anything beyond evaluating one set of supplied parameters. For the broad data-research domain that most tools actually serve, the read/research side is rich, but that is a completely different purpose from 'Take The Meeting', leaving the meeting feature as a disconnected dead end.

Resources